ARCT
NASDAQ · Biotechnology
Arcturus Therapeutics Holdin
$7.57
+0.55 (+7.83%)
Open$7.24
Previous Close$7.02
Day High$7.63
Day Low$7.01
52W High$27.70
52W Low$18.44
Volume—
Avg Volume112.2K
Market Cap215.10M
P/E Ratio20.95
EPS$1.02
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+248.9% upside
Current
$7.57
$7.57
Target
$26.41
$26.41
$16.23
$26.41 avg
$33.18
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 30.40M | 31.39M | 23.67M |
| Net Income | -5,676,909 | -5,088,256 | -3,711,629 |
| Profit Margin | -18.7% | -16.2% | -15.7% |
| EBITDA | -6,604,338 | -7,015,778 | -5,079,230 |
| Free Cash Flow | -5,135,953 | -5,929,972 | -4,352,810 |
| Rev Growth | +22.0% | +5.3% | +9.7% |
| Debt/Equity | 0.38 | 0.28 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |